SLC1A5 and prostate carcinoma: The efficacy of ASCT2 inhibition in curbing glutamine uptake has been demonstrated across various cancer types, including melanoma,[52] non‐small cell lung cancer,[53] prostate cancer,[54] and acute myeloid leukemia.[55] Kaplan‐Meier plots, coupled with the log‐rank (Mantel‐Cox) test highlighted the prognostic benefits associated with low ASCT2 expression in NSCLC (Figure S9F, Supporting Information).